New process for generic-drug price change submissions
We’ve introduced a faster and easier way for manufacturers to submit price change requests for generic drugs.
Introducing the new chair and vice-chair of our Board
We are pleased to announce our new chair and vice-char of our Board
The pCPA welcomes our acting deputy CEO
The pCPA is pleased to announce that Dr. Clifford Lo will be joining the pCPA team as acting deputy CEO.
Deputy CEO Dominic Tan assumes CEO duties of pCPA
Effective May 10, 2024, Dominic Tan has assumed the responsibilities of CEO of the pCPA on an interim basis.
Announcing the launch of our pCPA Temporary Access Process (pTAP)
Following consultations with stakeholders in the late summer and early fall of 2023, we have finalized the principles and conditions for pTAP.
Market exit updates for generic drugs
As of May 1, 2024, changes to the market exit process for generic drugs are in effect.
pTAP consultations: What we heard
In August 2023, the pCPA engaged with clinicians, patient groups and industry to present and hear feedback on a set of principles and conditions for pTAP.
The pCPA Inaugural Report, Marking a Year of Transformation
The pCPA Board of Directors is thrilled to release the organization’s inaugural report.
Notice of the Annual General Meeting 2023
Notice is hereby given that the first Annual General Meeting of the members of the pCPA will take place on October 25, 2023.
New pricing initiative for generic drugs
A new three-year pricing initiative for generic drugs will come into effect on October 1, 2023.